RAS-Wild-Type Metastatic Colon Cancer: When Sidedness Meets a Resectable Liver
The data saying right-sided, RAS-wild-type tumors don't benefit much from anti-EGFR therapy come almost entirely from patients whose disease was never going to be resectable — and this one might be.
T.W., a 45-year-old man, coaches a competitive youth swim team most evenings and mornings, and came in only because his wife insisted after months of him mentioning, always in passing, that his stools "looked different." A cecal mass was found on colonoscopy, biopsy-confirmed adenocarcinoma, RAS and BRAF wild-type on tumor sequencing, with three liver metastases on staging MRI — all in the right hepatic lobe, none larger than 2.5cm, technically resectable by the liver surgery team's own assessment if the disease shrinks enough to create a safer surgical margin. He has no other sites of disease and is otherwise in excellent physical condition.
Anti-EGFR therapy — cetuximab or panitumumab — requires RAS/RAF wild-type status to work at all, which T.W. has, but the pooled sidedness analyses of CALGB/SWOG 80405 and the FIRE-3 trial found that right-sided primary tumors derive little to no overall survival benefit from adding anti-EGFR therapy to chemotherapy, even when RAS/RAF wild-type, compared to a clear, substantial benefit in left-sided tumors — a finding now embedded directly into guideline preference for bevacizumab over anti-EGFR therapy in right-sided disease regardless of mutation status. But those sidedness analyses measured overall survival in populations where most patients had unresectable disease from the start. What anti-EGFR combinations have shown more consistently across sidedness, including in some right-sided subsets, is a higher objective response rate — the exact endpoint that matters most for a patient whose actual goal isn't just disease control, but shrinking three liver lesions enough for a surgeon to safely take them out. Nobody on the team disputes the sidedness survival finding itself; the actual disagreement is narrower and more specific — whether a result generated almost entirely in patients who were never surgical candidates should be read as decisive for one who, on today's imaging, plausibly is.
Multidisciplinary liver tumor board
Guideline preference for right-sided, RAS-wild-type disease is bevacizumab over anti-EGFR therapy, and that's built on real, replicated overall survival data from both CALGB/SWOG 80405 and FIRE-3's sidedness analyses. I understand the appeal of chasing response rate for a potentially resectable patient, but I'd want to be careful about overriding the strongest population-level survival evidence we have for a softer, more heterogeneous endpoint.
You're right that the survival data are strong — for the population those trials actually enrolled, which was overwhelmingly patients whose disease was never going to be resected either way. That's not T.W. His three lesions are small, unilobar, and borderline resectable today. What determines whether he gets an operation isn't which regimen extends median survival by some number of months in an unresectable cohort — it's which one shrinks his liver disease fastest and deepest in the next two months.
I'm not disputing the sidedness survival finding. I'm disputing that it was ever measuring the question we're actually asking for him.
Both of you are arguing from real, defensible endpoints — which is exactly why I don't think we need to resolve which trial's evidence "wins" today. Whatever regimen starts, repeat imaging at six to eight weeks tells us directly whether the response is deep enough to move toward surgery. If it isn't, we still have time to switch. The endpoint-mismatch argument is real, but it doesn't have to be settled in the abstract when we can just measure the thing we actually care about on a short timeline.
Agreed: FOLFIRI plus cetuximab for the first two months, with dedicated restaging MRI at seven weeks specifically to reassess resectability with the liver surgery team present at that review.
Not agreed as a settled principle, only as this case's specific plan: the medical oncologist's preference for guideline-concordant bevacizumab was not overridden lightly, and the team was explicit that this decision rests on T.W.'s individual convertibility, not a general claim that response-rate reasoning should override sidedness survival data whenever a right-sided tumor looks borderline resectable on first imaging.